5830415F09Rik Inhibitors

Chemicals classified as TrmO Inhibitors do not directly target the enzyme tRNA methyltransferase O. Instead, they impact various cellular processes that are upstream or ancillary to the function of TrmO. These compounds typically interfere with tRNA synthesis, maturation, or the methylation machinery itself, leading to an indirect reduction in TrmO activity.

Actinomycin D, Rifampicin, and Mithramycin A are compounds that bind to DNA, thereby inhibiting RNA polymerase activity and subsequently decreasing the synthesis of tRNA, the substrate for TrmO. α-Amanitin selectively inhibits RNA polymerase II and III, which are responsible for synthesizing various classes of RNA, including tRNA. Neplanocin A and Mycophenolic acid disrupt the balance of nucleotide pools or the methylation cycle, consequently affecting the methyltransferase activity of TrmO. Antimetabolites like 5-fluorouracil, 5-azacytidine, Zebularine, and Decitabine are nucleoside analogs that can be incorporated into RNA molecules, leading to faulty tRNA molecules that may not be proper substrates for TrmO. Lastly, Hydralazine is known for its effects on DNA methylation but can also have consequences for RNA methylation patterns, thereby potentially affecting TrmO indirectly.